Obermatt

Kamada

NSQ:KMDA · IL0010941198
BiotechnologySmall

360

82
Profit price3
Owner Earnings Yield83
Dividend Yield1
Price/Sales48
EV / Gross Profit45
Price/Book63
Return on Capital89
Cash Return on Capital87
Return on Equity87
EBIT Margin87
Gross Profitability65
Accruals24
Owner Earnings Margin82
Sales growth34
Profit growth39
Reinvestment16
Price momentum41
Debt load85
Refinancing77
Debt Payback100
Liquidity96
Analyst ratings85
Expectations trend50
Market mood55
Value Creation12/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Kamada clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryIsrael
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeTASE
Founded1990
Employees202
Websitekamada.com
ISINIL0010941198
Last UpdateApr 2, 2026
Themes
Infectious DiseasesChronic DiseasesHealth DiagnosticsHematologyImmunologyRespiratoryOncologyBiopharmaBiotechnologyHealth CareTherapeutics

Description

Kamada Ltd. is a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field. The company’s strategy is focused on driving profitable g…

Analysis

Quality compounder

Kamada Ltd. is a quality compounder: a well-run business trading at a price that reflects what it is worth. One caution: reported profits have recently run ahead of actual cash, which we track closely.

The price is fair. You pay 17.1× its owner earnings: the cash an owner could take out each year, which is in the historically fair zone.

The trajectory is moderate and the balance sheet is sturdy. The company scores 12/20 on our value-creation score: creating some value.

What to watch: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
46
2026

All-time high

87

Mar 2026

All-time low

46

Jun 2026

Average rank

67

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
48
Price/Earnings
23
Price/Book
63
Dividend Yield
1
Value (overall)
24

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Kamada with its peers
NovoCure
NSQ:NVCR
42
CountryJersey
IndustryHealth Care Equipment & Supplies
SizeMedium
Full Stock Analysis →
Pharming
AEX:PHARM
77
CountryNetherlands
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
OKYO Pharma
NAQ:OKYO
40
CountryUK
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
NewAmsterdam Pharma Company
NMQ:NAMS
16
CountryNetherlands
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
InMode
NSQ:INMD
86
CountryIsrael
IndustryHealth Care Equipment & Supplies
SizeSmall
Full Stock Analysis →
Metlen Energy & Metals
LSE:MTLN
12
CountryUK
IndustryIndustrial Conglomerates
SizeLarge
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →